These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38922538)

  • 1. Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.
    Tan K; Wang A; Zheng Y; Wang S; Wang C; Li J; Lu X; Dong H; Zheng J; Cui H
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38922538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.
    Liu SJ; Yan LJ; Wang HC; Ding ZN; Liu H; Zhang X; Pan GQ; Han CL; Tian BW; Yang XR; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
    Oncologist; 2024 Jun; ():. PubMed ID: 38940446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Cai Z; Zhan P; Song Y; Liu H; Lv T
    Transl Lung Cancer Res; 2022 Aug; 11(8):1555-1566. PubMed ID: 36090645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Huang Y; Ma W; Wu D; Lyu M; Zheng Q; Wang T; Zhou J; Liu C
    Transl Lung Cancer Res; 2024 Jul; 13(7):1559-1584. PubMed ID: 39118883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhou Y; Chen H; Tang L; Feng Y; Tao Y; Huang L; Lou N; Shi Y
    Immunotherapy; 2023 Feb; 15(3):209-220. PubMed ID: 36710655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Sep; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
    Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
    Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
    Front Oncol; 2021; 11():704475. PubMed ID: 34631533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.